^○Shunsuke Saito^1,2, Kazuhisa Uchida² (1.Synplogen Co., Ltd., Medical Business Unit, 2.Kobe University, Graduate School of Science, Technology and Innovation)

^○Takenori Yamamoto, Yasunori Uchida, Tokuyuki Yoshida, Nobumichi Ohoka, Takuma Yamashita, Eriko Uchida, Takao Inoue (Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences)

^○Takuma Yamashita, Takenori Yamamoto, Eriko Uchida, Takao Inoue (National Institute of Health Sciences)

^○Koichiro Aya, Takefumi Sone, Tsuyoshi Okumo, Tatsuya Kameyama, Masanori Takayama, Akiyuki Sato (TAKARA BIO INC.)

^○Kouhei Yoshida^1,2, Yuji Tsunekawa², Kento Kurihara¹, Kazuya Watanabe¹, Yuriko Makino¹, Keita Omura¹, Toru Tanaka¹, Teruhiko Ide¹, Takashi Okada² (1.Tosoh Corporation, Life Science Research Laboratory, 2.Division of Molecular and Medical Genetics, Center for Gene and Cell Therapy, The Institute of Medical Science, The University of Tokyo)

^○Sereirath Soth (Department of Biotechnology, Graduate School of Engineering, Osaka University)

^○Takahiro Maruno^1,2, Takaaki Kurinomaru¹, Masanori Noda¹, Mitsuko Fukuhara^1,2, Kiichi Hirohata², Yasuo Tsunaka², Yuki Yamaguchi², Tetsuo Torisu², Susumu Uchiyama² (1.U-Medico Inc., 2.Graduate School of Engineering, Osaka University)